OBJECTIVES: The PI3K/AKT pathway is frequently activated in endometrial carcinoma (EC) mainly due to mutations in the PIK3CA and PTEN genes. These events are common and believed to be the key to endometrial carcinogenesis. Recently, a somatic activating mutation in the AKT1 gene (E17K) was identified in several cancer types. In this study we explored the frequency of this AKT1 mutation in endometrial carcinoma. METHODS: Tumor DNA, extracted from 73 EC was analyzed for AKT1 E17K mutation (G49A) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In addition, the tumors were screened for coexisting common mutations in PTEN, PIK3CA and KRAS. RESULTS: The AKT1 E17K mutation was detected in 4% of EC. One of the AKT1-mutated tumors showed coexisting PTEN loss-of-function mutation. CONCLUSION: We identified the AKT1 E17K mutation in 4% of endometrial carcinomas. The presence of double AKT1/ PTEN mutants is in accord with the hypothesis that in EC more than one hit is required to completely activate the PI3K pathway. Furthermore, AKT1 mutations were limited to high grade, advanced stage tumors suggesting that this mutation confers a more aggressive tumor behavior.
OBJECTIVES: The PI3K/AKT pathway is frequently activated in endometrial carcinoma (EC) mainly due to mutations in the PIK3CA and PTEN genes. These events are common and believed to be the key to endometrial carcinogenesis. Recently, a somatic activating mutation in the AKT1 gene (E17K) was identified in several cancer types. In this study we explored the frequency of this AKT1 mutation in endometrial carcinoma. METHODS: Tumor DNA, extracted from 73 EC was analyzed for AKT1E17K mutation (G49A) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In addition, the tumors were screened for coexisting common mutations in PTEN, PIK3CA and KRAS. RESULTS: The AKT1E17K mutation was detected in 4% of EC. One of the AKT1-mutated tumors showed coexisting PTEN loss-of-function mutation. CONCLUSION: We identified the AKT1E17K mutation in 4% of endometrial carcinomas. The presence of double AKT1/ PTEN mutants is in accord with the hypothesis that in EC more than one hit is required to completely activate the PI3K pathway. Furthermore, AKT1 mutations were limited to high grade, advanced stage tumors suggesting that this mutation confers a more aggressive tumor behavior.
Authors: David M Hyman; Lillian M Smyth; Mark T A Donoghue; Shannon N Westin; Philippe L Bedard; Emma J Dean; Hideaki Bando; Anthony B El-Khoueiry; José A Pérez-Fidalgo; Alain Mita; Jan H M Schellens; Matthew T Chang; Jonathan B Reichel; Nancy Bouvier; S Duygu Selcuklu; Tara E Soumerai; Jean Torrisi; Joseph P Erinjeri; Helen Ambrose; J Carl Barrett; Brian Dougherty; Andrew Foxley; Justin P O Lindemann; Robert McEwen; Martin Pass; Gaia Schiavon; Michael F Berger; Sarat Chandarlapaty; David B Solit; Udai Banerji; José Baselga; Barry S Taylor Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544